Glutamate binding-site ligands of NMDA receptors

Current Medicinal Chemistry

Volumn 18, Issue 36, 2011, Pages 5483-5506

  Bonaccorso, C ^a   Micale, N ^a   Ettari, R ^a   Grasso, S ^a   Zappala M ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Competitive agonists; Competitive antagonists; Glutamate; NMDA receptors

Indexed keywords

4 METHYLGLUTAMIC ACID; ASPARTIC ACID; CONANTOKIN G; CYCLIN DEPENDENT KINASE 5; DECAHYDROISOQUINOLINE; DYSIHERBAINE; GLUTAMIC ACID; GLYCINE; IBOTENIC ACID; ISOXAZOLINE DERIVATIVE; LIGAND; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OMEGA PHOSPHONO ALPHA AMINO ACID DERIVATIVE; QUINOLINIC ACID; QUINOXALINEDIONE DERIVATIVE; SERINE; TETRAHYDROISOQUINOLINE; TRICHOLOMIC ACID; UNCLASSIFIED DRUG;

ACUTE DISEASE; ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CALCIUM TRANSPORT; CARBOXY TERMINAL SEQUENCE; CEREBELLUM; CHRONIC DISEASE; CONDUCTANCE; CONFORMATIONAL TRANSITION; DRUG ISOLATION; DRUG TOLERABILITY; ENANTIOSELECTIVITY; EXCITATORY POSTSYNAPTIC POTENTIAL; EXCITOTOXICITY; GRANULE CELL; HALLUCINATION; HIPPOCAMPUS; HUMAN; INTRACELLULAR SIGNALING; ION CONDUCTANCE; LIGAND BINDING; MEMBRANE STEADY POTENTIAL; MEMORY DISORDER; MOTOR DYSFUNCTION; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; PARTIAL AGONISM; PROTEIN ASSEMBLY; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PURKINJE CELL; RACEMIC MIXTURE; SITE DIRECTED MUTAGENESIS; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

EID: 84055183958     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798347225     Document Type: Article

References (197)

1. Riedel, G.; Platt, B.; Micheau, J. Glutamate receptor function in learning and memory. Behav. Brain Res., 2003, 140, 1-47. (Pubitemid 36313239)
2. Coyle, J.T.; Leski, M.L.; Morrison, J.H. The diverse roles of L-glutamic acid in brain signal transduction. In: Neuropsychopharmacology: The Fifth Generation of Progress, 5th Ed.; Lippincott Williams & Wilkins: Philadelphia, 2002; pp 71-90.
3. Traynelis, S.F.; Wollmuth, L.P.; McBain, C.J.; Menniti, F.S.; Vance, K.M.; Ogden, K.K.; Hansen, K.B.; Yuan, H.; Myers, S.J.; Dingledine, R. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev., 2010, 62, 405-496.
4. Kemp, J.A.; McKernan, R.M. NMDA receptor pathways as drug targets. Nature Neurosci, 2002, 5, 1039-1042. (Pubitemid 35247194)
5. Bräuner-Osborne, H.; Egebjerg, J.; Nielsen, E.Ø.; Madsen, U.; Krogsgaard-Larsen, P. Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem., 2000, 43, 2609-2645. (Pubitemid 30463912)
6. Laube, B.; Kuhse, J.; Betz, H. Evidence for a tetrameric structure of recombinant NMDA receptors. J. Neurosci., 1998, 18, 2954-2961. (Pubitemid 28163225)
7. Collingridge, G.L.; Olsen, R.W.; Peters, J.; Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology, 2009, 56, 2-5.
8. Paoletti, P.; Neyton, J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol., 2007, 7, 39-47. (Pubitemid 46238036)
9. Cull-Candy, S.; Brickley, S.; Farrant, M. NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol., 2001, 11, 327-35. (Pubitemid 32524098)
10. Sobolevsky, A.I.; Rosconi, M.P.; Gouaux, E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature, 2009, 462, 745-756.
11. Sasaki, Y.F.; Rothe, T.; Premkumar, L.S.; Das, S.; Cui, J.; Talantova, M.V.K.; Gong, X.; Chan, S.F.; Zhang, D.; Nakanishi, N.; Sucher, N.J.; Lipton, S.A. Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons. J. Neurophysiol., 2002, 87, 2052-2063. (Pubitemid 34670767)
12. Conti, P.; Tamburini, L.; Pinto, A.; Blondel, A.; Minoprio, P.; Mozzarelli, A.; De Micheli, C. Drug discovery targeting amino acid racemases. Chem. Rev., 2011, DOI: 10.1021/cr2000702.
13. Yao, Y.; Mayer, M.L. Characterization of a soluble ligand binding domain of the NMDA receptor regulatory subunit NR3A. J. Neurosci., 2006, 26, 4559-4566. (Pubitemid 44315355)
14. Madry, C.; Betz, H.; Geiger, J.R.P.; Laube, B. Supralinear potentiation of NR1/NR3A excitatory glycine receptors by Zn2+ and NR1 antagonist. Proc. Natl. Acad. Sci., 2008, 105, 12563-12568.
15. Gielen, M.; Retchless, B.S.; Mony, L.; Johnson, J.W.; Paoletti, P. Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature, 2009, 459, 703-707.
16. Karakas, E.; Simorowski, N.; Furukawa, H. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Nature, 2011, 475, 249-253.
17. Childers, W.E.; Baudy, R.B.Jr. N-Methyl-D-aspartate antagonists and neuropathic pain: the search for relief. J. Med. Chem., 2007, 50, 2557-2562.
18. Chazot, P.L. The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr. Med. Chem., 2004, 11, 389-396. (Pubitemid 38240214)
19. Borza, I.; Domany, G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr. Top. Med. Chem., 2006, 6, 687-695.
20. Layton, M.E.; Kelly, M.J.3rd; Rodzinak, K.J. Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Curr. Top. Med. Chem., 2006, 6, 697-709.
21. Koller, M.; Urwyler, S. Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006. Expert Opin. Ther. Patents, 2010, 20, 1683-1702.
22. Huggins, D.J.; Grant, G.H. The function of the amino terminal domain in NMDA receptor modulation. J. Mol. Graph. Model, 2005, 23, 381-388. (Pubitemid 40164751)
23. Johnson, J.W. Acid tests of N-methyl-D-aspartate receptor gating basics. Mol. Pharmacol. 2003, 63, 1199-1201. (Pubitemid 36627211)
24. Mayer, M.L. Glutamate receptors at atomic resolution. Nature, 2006, 440, 456-462.
25. Paoletti P.; Perin-Dureau F.; Fayyazuddin A.; Le Goff A.; Callebaut I.; Neyton J. Molecular organization of a zinc binding N-terminal modulatory domain in a NMDA receptor subunit. Neuron, 2000, 28, 911-925. (Pubitemid 32038081)
26. Rachline, J.; Perin-Dureau, F.; Le Goff, A.; Neyton, J.; Paoletti, P. The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J. Neurosci., 2005, 25, 308-317. (Pubitemid 40105601)
27. Furukawa, H.; Gouaux, E. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J., 2003, 12, 2873-2885. (Pubitemid 36758609)
28. Inanobe, A.; Furukawa, H.; Gouaux. E. Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. Neuron, 2005, 47, 71-84. (Pubitemid 40922851)
29. Hansen, K.B.; Clausen, R.P.; Bjerrum, E.J.; Bechmann, C.; Greenwood, J.R.; Christensen, C.; Kristensen, J.L.; Egebjerg, J.; Bräuner-Osborne H. Tweaking agonist efficacy at N-methyl-D-aspartate receptors by site-directed mutagenesis. Mol. Pharmacol., 2005, 68, 1510-1523. (Pubitemid 41654335)
30. Burnashev, N.; Schoepfer, R.; Monyer, H.; Ruppersberg, J.P.; Gunther, W.; Seeburg, P.H.; Sakmann, B. Control by asparagine residues of calcium permeability and magnesium blockade in the NMDA receptor. Science, 1992, 257, 1415-1459.
31. O'Leary, T.; Wyllie, D.J.A. Single-channel properties of N-methyl-Daspartate receptors containing chimaeric GluN2A/GluN2D subunits. Biochem. Soc. Trans., 2009, 37, 1347-1354.
32. Chaffey, H.; Chazot, P.L. NMDA receptor subtypes: structure, function and therapeutics. Curr. Anaesth. Crit. Care, 2008, 19, 183-201.
33. Matsuda, K.; Kamiya, Y.; Matsuda, S.; Yuzaki, M. Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Brain Res. Mol. Brain Res., 2002, 100, 43-52. (Pubitemid 34465577)
34. Nishi, M.; Hinds, H.; Lu, H.P.; Kawata, M.; Hayashi, Y. Motoneuronspecific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J. Neurosci., 2001, 21, 1-6.
35. Loftis, J.M.; Janowsky, A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther., 2003, 97, 55-85. (Pubitemid 35477804)
36. Laurie, D.J.; Bartke, I.; Schoepfer, R.; Naujoks, K.; Seeburg, P.H. Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. Brain Res Mol Brain Res, 1997, 51, 23-32. (Pubitemid 27504028)
37. Wenzel, A.; Villa, M.; Mohler, H.; Benke, D. Developmental and Regional Expression of NMDA Receptor Subtypes Containing the NR2D Subunit in Rat Brain. J. Neurochem., 1996, 66, 1240-1248. (Pubitemid 26065924)
38. Cull-Candy, S.G.; Leszkiewics, D.N. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE, 2004, 16, 1-9.
39. Eriksson, M.; Nilsson, A.; Froelich-Fabre, S.; Akesson, E.; Dunker, J.; Seiger, A. Cloning and expression of the human N-methyl-D-aspartate receptor subunit NR3A. Neurosci. Lett., 2002, 321, 177-181. (Pubitemid 34203828)
40. Popescu, G. Mechanism-based targeting of NMDA receptor functions. Cell Mol. Life Sci., 2005, 62, 2100-2111. (Pubitemid 41291666)
41. Cooke, S.F.; Bliss, T.V.P. Plasticity in the human central nervous system. Brain, 2006, 129, 1659-1673. (Pubitemid 43999401)
42. Arundine, M.; Tymianski, M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium, 2003, 34, 325-337. (Pubitemid 37021228)
43. Lester, R.A.; Clements, J.D.; Westbrook, G.L.; Jahr, C.E. Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents. Nature, 1990, 346, 565-567.
44. Dzubay, J.A.; Jahr, C.E. Kinetics of NMDA channel opening. J. Neurosci., 1996, 16, 4129-4134. (Pubitemid 26192408)
45. Erreger, K.; Chen, P.E.; Wyllie, D.J.A.; Traynelis, S.F. Glutamate receptor gating. Crit. Rev. Neurobiol., 2004, 16, 187-224. (Pubitemid 40314700)
46. Vance, K.M.; Somorowski, N.; Traynelis, S.F.; Furukawa, H. Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors. Nature Comm. 2011, 2:294.
47. Chen, N.; Moshaver, A.; Raymond, L.A. Differential sensitivity of recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition. Mol. Pharmacol., 1997, 51, 1015-1023. (Pubitemid 27249135)
48. Fayyazuddin, A.; Villarroel, A.; Le Goff, A.; Lerma, J.; Neyton. J. Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors. Neuron, 2000, 25, 683-694.
49. Low, C.M.; Zheng, F.; Lyuboslavsky, P.; Traynelis. S.F. Molecular determinants of coordinated proton and zinc inhibition of N-methyl-Daspartate NR1/NR2A receptors. Proc. Acad. Natl. Sci., 2000, 97, 11062-11067.
50. Legendre, P.; Westbrook G.L. The inhibition of single N-methyl-D-aspartateactivated channels by zinc ions on cultured rat neurones. J. Physiol., 1990, 429, 429-449. (Pubitemid 20327560)
51. Paoletti, P.; Perin-Dureau, F.; Fayyazuddin, A.; Le Goff, A.; Callebaut, I.; Neyton, J. Molecular organization of a zinc binding N-terminal modulatory domain in a NMDA receptor subunit. Neuron, 2000, 28, 911-955.
52. Karakas, E.; Simorowski, N.; Furukawa. H. Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit. EMBO J., 2009, 28, 3910-3920.
53. Liu, Y.; Zhang, J. Recent development in NMDA receptors. Chinese Med. J., 2000, 113, 948-956.
54. Johnson, T.D. Modulation of channel function by polyamines. Trends Pharmacol. Sci., 1996, 17, 22-27. (Pubitemid 26027737)
55. Kashiwagi, K.; Pahk, A.J.; Masuko, T.; Igarashi, K.; Williams, K. Block and modulation of N-methyl-D-aspartate receptors by polyamines and protons: role of amino acid residues in the transmembrane and pore-forming regions of NR1 and NR2 subunits. Mol Pharmacol., 1997, 52, 701-713. (Pubitemid 27443993)
56. Wang, Y.T.; Salter, M.W. Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature, 1994, 69, 233-235. (Pubitemid 24154800)
57. Salter, M.W.; Kalia, L.V. Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci., 2004, 5, 317-328. (Pubitemid 38478658)
58. Sanchez-Pérez, A.M.; Felipe, V. Serines 890 and 896 of the NMDA receptor subunit NR1 are differentially phosphorylated by protein kinase C isoforms. Neurochem. Int., 2005, 47, 84-91. (Pubitemid 40848697)
59. Scott, D.B.; Blanpied, T.A.; Ehlers, M.D. Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacol., 2003, 45, 755-767. (Pubitemid 38340361)
60. Li, B.S.; Sun, M.K.; Zhang, L.; Takahashi, S.; Ma, W.; Vinade, L.; Kulkarni, A.B.; Brady, R.O.; Pant, H.C. Regulation of NMDA receptors by cyclindependent kinase-5. Proc. Natl. Acad. Sci., 2001, 98,12742-12747. (Pubitemid 33020016)
61. Wang, J.; Liu, S.H.; Fu, Y.P.; Wang, J.H.; Lu, Y.M. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat. Neurosci., 2003, 6, 1039-1047. (Pubitemid 37186195)
62. Zheng, F.; Gingrich, M.B.; Traynelis, S.F.; Conn P.J. Tyrosine kinase potentiates NMDA receptor currents by reducing tonic zinc inhibition. Nat. Neurosci., 1998, 1, 185-191.
63. Xiong, Z.G.; Pelkey, K.A.; Lu, W.Y.; Lu, Y.M.; Roder, J.C.; MacDonald, J.F.; Salter, M.W. Src potentiation of NMDA receptors in hippocampal and spinal neurons is not mediated by reducing zinc inhibition. J. Neurosci., 1999, 19, RC37.
64. Cheung, H.H., Gurd, J.W. Tyrosine phosphorylation of the N-methyl-Daspartate receptor by exogenous and postsynaptic density-associated Srcfamily kinases. J. Neurochem., 2001, 78, 524-534. (Pubitemid 32729980)
65. Nakazawa, T.; Komai, S.; Tezuka, T.; Hisatsune, C.; Umemori, H.; Semba, K.; Mishina, M.; Manabe, T.; Yamamoto. T. Characterization of fynmediated tyrosine phosphorylation stes on GluR2 (NR2B) subunit of the Nmethyl-D-aspartate receptor. J. Biol. Chem., 2001, 276, 693-699. (Pubitemid 32050862)
66. Snyder, E.M.; Nong, Y.; Almeida, C.G.; Paul, S.; Moran, T.; Choi, E.Y.; Nairn, A.C.; Salter, M.W.; Lombroso, P.J.; Gouras, G.K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-. Nat. Neurosci., 2005, 8, 1051-1058. (Pubitemid 41061516)
67. Chung, H.J.; Huang, Y.H.; Lau, L.F.; Huganir, R.L. Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. J. Neurosci., 2004, 24, 10248-10259. (Pubitemid 39492052)
68. Lu, Y.M.; Roder, J.C.; Davidow, J.; Salter, M.W. Src activation in the induction of long-term potentiation in CA1 hippocampal neurons. Science, 1998, 279, 1363-1368.
69. Bayer, K.U.; De Koninck, P.; Leonard, A.S.; Hell, J.W.; Schulman. H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature, 2001, 411, 801-805. (Pubitemid 32588103)
70. Barria, A.; Malinow, R. NMDA receptor subunit composition controls synaptic plasticity by regulating binding to CaMKII. Neuron, 2005, 48, 289-301. (Pubitemid 41476362)
71. Chen, B.S.; Braud, S.; Badger, J.D.2nd; Isaac, J.T.R.; Roche K.W. Regulation of NR1/NR2C N-methyl-D-aspartate (NMDA) receptors by phosphorylation. J. Biol. Chem., 2006, 281, 16583-16590.
72. Chen, B.S.; Roche K.W. Growth factor-dependent trafficking of cerebellar NMDA receptors via protein kinase B/Akt phosphorylation of NR2C. Neuron, 2009, 62, 471-478.
73. Standley, S.; Baudry, M. The role of glycosylation in ionotropic glutamate receptor ligand binding, function, and trafficking.Cell Mol Life Sci., 2000, 57, 1508-1516.
74. Hayashi, T.; Thomas, G.; Huganir, R.L. Dual palmitoylation of NR2 subunits regulates NMDA receptor trafficking. Neuron, 2009, 64, 213-226.
75. Choi, Y.B.; Tenneti, L.; Le, D.A.; Ortiz, J.; Bai, G.; Chen H.S.V.; Lipton S.A. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci., 2000, 3, 15-21. (Pubitemid 30126343)
76. Choi ,Y.B.; Lipton, S.A. Redox modulation of the NMDA receptor. Cell Mo.l Life Sci., 2000, 57, 1535-1541.
77. Choi, Y.; Chen, H.V.; Lipton, S.A. Three pairs of cysteine residues mediate both redox and Zn2+ modulation of the NMDA receptor. J. Neurosci., 2001, 21, 392-400. (Pubitemid 32107430)
78. Javitt, D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry, 2004, 9, 984-997. (Pubitemid 39524288)
79. Clausen, R.P.; Hansen, K.B.; Calí, P.; Nielsen, B.; Greenwood, J.R.; Begtrup, M.; Egebjerg, J.; Bräuner-Osborne, H. The respective Nhydroxypyrazole analogs of the classical glutamate receptor ligands ibotenic acid and (RS)-2-amino-2-(3-hydroxy-5-methyl-4-isoxazolyl)acetic acid. Eur. J. Pharmacol., 2004, 499, 35-44. (Pubitemid 39201209)
80. Curtis, D.R.; Watkins, J.C. The excitation and depression of spinal neurones by structurally related amino acids J. Neurochem., 1960, 6, 117-141.
81. Tikhonova, I.G.; Baskin, I.I.; Palyulin, V.A.; Zefirov, N.S.; Bachurin, S.O. Structural basis for understanding structure-activity relationships for the glutamate binding site of the NMDA receptor. J. Med. Chem., 2002, 45, 3836-3843. (Pubitemid 35033449)
82. Kunishima, N.; Shimada, Y.; Tsuji, Y.; Sato, T.; Yamamoto, M.; Kumasaka, T.; Nakanishi, S.; Jingami, H.; Morikawa, K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature, 2000, 407, 971-977.
83. Furukawa, H.; Singh, S.K.; Mancusso, R.; Gouaux, E. Subunit arrangement and function in NMDA receptors. Nature, 2005, 438, 185-192. (Pubitemid 41599865)
84. Laube, B.; Schemm, R.; Betz H. Molecular determinants of ligand discrimination in the glutamate-binding pocket of the NMDA receptor. Neuropharmacol., 2004, 47, 994-1007. (Pubitemid 39535840)
85. Chen, P.E.; Geballe, M.T.; Stansfeld, P.J.; Johnston, A.R.; Yuan, H.; Jacob, A.L.; Snyder, J.P.; Traynelis, S.F.; Wyllie, D.J.A. Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol, 2005, 67, 1470-1484. (Pubitemid 40594146)
86. Grimwood, S.; Foster, A.C.; Kemp, J.A. The pharmacological specificity of N-methyl-D-aspartate receptors in rat cerebral cortex: correspondence between radioligand binding and electrophysiological measurements. Br. J. Pharmacol., 1991, 103, 1385-1392
87. Erreger, K.; Geballe, M.T.; Kristensen, A.S.; Chen, P.E.; Hansen, K.B.; Lee, C.J.; Yuan, H.; Le. P.; Lyuboslavsky P.N.; Micale, N.; Joørgensen, L.; Clausen, R.P.; Wyllie, D.J.; Snyder, J.P.; Traynelis, S.F. Subunit-specific agonist activity for glutamate analogs at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol. Pharmacol., 2007, 72, 907-920. (Pubitemid 47481414)
88. Donevan, SD.; Beg, A.; Gunther J.M.; Twyman, R.E. The methylglutamate, SYM 2081, is a potent and highly selective agonist at kainate receptors. J. Pharmacol. Exp. Ther., 1998, 285, 539-545. (Pubitemid 28237430)
89. Pullan, L.M.; Olney, J.W.; Price, M.T.; Compton, R.P.; Hood, W.F.; Michel, J.; Monahan, J.B. Excitatory amino acid receptor potency and subclass specificity of sulfur-containing amino acids. J. Neurochem., 1987, 49, 1301-1307. (Pubitemid 17151589)
90. Pellicciari, R.; Marinozzi, M.; Macchiarulo, A.; Fulco, M.C.; Gafarova, J.; Serpi, M.; Giorgi, G.; Nielsen, S.; Thomsen, C. Synthesis, molecular modeling studies, and preliminary pharmacological characterization of all possible 2-(2'-sulfonocyclopropyl)glycine stereoisomers as conformationally constrained L-homocysteic acid analogs. J. Med. Chem., 2007, 50, 4630-4641. (Pubitemid 47463237)
91. Lunn, W.H.W.; Schoepp, D.D.; Calligaro, D.; Vasileff, R.T.; Heinz, L.J.; Salhoff, C.R.; O'Malley, P.J. DL-Tetrazole-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacy. J. Med. Chem., 1992, 35, 4608-4612. (Pubitemid 23006680)
92. Curry, K.; Peet, M.J.; Magnuson, D.S.K.; McLennan, H. Synthesis, resolution, and absolute configuration of the isomers of the neuronal excitant l-amino-1,3-cyclopentanedicarboxylic acid. J. Med. Chem., 1988, 31, 864-867. (Pubitemid 18097111)
93. Schoepp, D.D.; Johnson, B.G.; Salhoff, C.R.; McDonald, J.W.; Johnston, M.V. In vitro and in vivo pharmacology of trans-and cis-(+)-1-amino-1,3- cyclopentanedicarboxylic acid: dissociation of metabotropic and ionotropic excitatory amino acid receptor effects. J. Neurochem., 1991, 56, 1789-1796.
94. Allan, R.D.; Hanrahan, J.R.; Hambley, T.W.; Johnston, G.A.R.; Mewett, K.N.; Mitrovic, A.D. Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-L-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. J. Med. Chem., 1990, 33, 2905-2915. (Pubitemid 20312163)
95. Shinozaki, H.; Ishida, M.; Shimamoto, K.; Ohfune, Y. A conformationally restricted analogue of L-glutamate, the (2S,3R,4S) isomer of L-(carboxycyclopropyl)glycine, activates the NMDA-type receptor more markedly than NMDA in the isolated rat spinal cord. Brain Res., 1989, 480, 355-359. (Pubitemid 19050236)
96. Kawai, M.; Horikawa, Y.; Ishihara, T.; Shimamoto, K.; Ohfune, Y. 2-(Carboxycyclopropyl)glycines: binding, neurotoxicity and induction of intracellular free Ca2+ increase. Eur. J. Pharmacol., 1992, 211, 195-202.
97. Hayashi, Y.; Tanabe, Y.; Aramori, I.; Masu, M.; Shimamoto, K.; Ohfune, Y.; Nakanishi, S. Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in chinese hamster ovary cells. Br. J. Pharmacol., 1992, 107, 539-543.
98. Sivaprakasam, M.; Hansen, K.B.; David, O.; Nielsen, B.; Traynelis, S.F.; Clausen, R.P.; Couty, F.; Bunch, L. Stereocontrolled synthesis and pharmacological evaluation of azetidine-2,3-dicarboxylic acids at NMDA receptors. ChemMedChem, 2009, 4, 110-117.
99. Madsen, U.; Brehm, L.; Schaumburg, K.; Joørgensen, V.S.; Krogsgaard-Larsen, P. Relationship between structure, conformational flexibility, and biological activity of agonists and antagonists at the N-methyl-D-aspartic acid subtype of excitatory amino acid receptors J. Med. Chem., 1990, 33, 374-380. (Pubitemid 20038220)
100. Orrenius, S.; McCabe, M.J.Jr.; Nicotera, P. Ca2+-dependent mechanisms of cytotoxicity and programmed cell death. Toxicol Lett, 1992, 64-65, 357-364. (Pubitemid 23018774)
101. Brauner-Osborne, H.; Nielsen, B.; Krogsgaard-Larsen, P. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Eur. J. Pharmacol., 1998, 350, 311-316.
102. Hermit, M.B.; Greenwood, J.R.; Nielsen, B.; Bunch, L.; Joørgensen, C.G.; Vestergaard, H.T.; Stensboøl, T.B.; Sanchez, C.; Krogsgaard-Larsen, P.; Madsen U.; Bräuner-Osborne H. Ibotenic acid and thioibotenic acid: a remarkable difference in activity at group III metabotropic glutamate receptors Eur J Pharmacol, 2004, 486, 241-250. (Pubitemid 38231053)
103. Calí, P.; Begtrup, M. Synthesis of 1-hydroxypyrazole glycine derivatives Tetrahedron, 2002, 58, 1595-1605. (Pubitemid 34173029)
104. Stensboøl, T.B; Uhlmann, P.; Morel, S.; Eriksen, B.L.; Felding, J.; Kromann, H.; Hermit, M.B.; Greenwood, J.R.; Braüner-Osborne, H.; Madsen, U.; Junager, F.; Krogsgaard-Larsen, P.; Begtrup, M.; Vedsoø, P. Novel 1-hydroxyazole bioisosteres of glutamic acid. Synthesis, protolytic properties, and pharmacology J. Med.Chem., 2002, 45, 19-31. (Pubitemid 34041046)
105. Clausen, R.P.; Christensen, C.; Hansen K.B.; Greenwood, J.R.; Joørgensen, L.; Micale, N.; Madsen, J.C.; Nielsen, B.; Egebjerg, J.; Bräuner-Osborne, H.; Traynelis, S.F.; Kristensen, J.L. N-Hydroxypyrazolyl glycine derivatives as selective N-methyl-D-aspartic acid receptor ligands. J. Med. Chem., 2008, 51, 4179-4187. (Pubitemid 352036533)
106. Madsen, U.; Ferkany, J.W.; Jones, B.E.; Ebert, B.; Johansen, T.N.; Holm, T.; Krogsgaard-Larsen, P. NMDA receptor agonists derived from ibotenic acid. Preparation, neuroexcitation and neurotoxicity. Eur. J. Pharmacol., 1990, 189, 381-391.
107. Madsen, U.; Frydenvang, K.; Ebert, B.; Johansen, T.N.; Brehm, L.; Krogsgaard-Larsen, P. N-Methyl-D-aspartic acid receptor agonists: resolution, absolute stereochemistry, and pharmacology of the enantiomers of 2-amino-2-(3-hydroxy-5-methyl-4-isoxazolyl)acetic acid. J. Med. Chem., 1996, 39, 183-190.
108. Joørgensen, C.G.; Bräuner-Osborne, H.; Nielsen, B.; Kehler, J.; Clausen, R.P.; Krogsgaard-Larsen, P.; Madsen, U. Novel 5-substituted 1-pyrazolol analogs of ibotenic acid: synthesis and pharmacology at glutamate receptors. Bioorg. Med. Chem., 2007, 15, 3524-3538. (Pubitemid 46541712)
109. Joørgensen, C.G.; Clausen, R.P.; Hansen, K.B.; Bräuner-Osborne, H.; Nielsen, B.; Metzler, B.; Kehler, J.; Krogsgaard-Larsen, P.; Madsen, U. Synthesis and pharmacology of glutamate receptor ligands: new isothiazole analogs of ibotenic acid. Org Biomol Chem., 2007, 5, 463-471. (Pubitemid 46168250)
110. Maier, W.; Schemm, R.; Grewer, C.; Laube, B. Disruption of interdomain interactions in the glutamate binding pocket affects differentially agonist affinity and efficacy of N-methyl-D-aspartate receptor activation. J. Biol. Chem., 2007, 282, 1863-1872. (Pubitemid 47076721)
111. Risgaard, R.; Hansen, K.B.; Clausen, R.P. Partial agonists and subunitselectivity at NMDA receptors Chem. Eur. J., 2010, 16, 13910-13918.
112. Lolli, M.L.; Giordano, C.; Pickering, D.S.; Rolando, B.; Hansen, K.B.; Foti, A.; Contreras-Sanz, A.; Amir, A.; Fruttero, R.; Gasco, A.; Nielsen, B.; Johansen, T.N. 4-Hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologs. J. Med. Chem., 2010, 53, 4110-4118.
113. Takemoto, T.; Nakajima, T. Constituents of indigenous fungi I. Isolation of the insecticidal constituent from Tricholoma muscarium. J. Pharm. Soc. Jpn., 1964, 84, 1183-1186.
114. Takemoto, T.; Yokobe, T.; Nakajima, T. Studies on the constituents of indogenous fungi. II. Isolation of the flycidal constituent from Amanita Strobiliformis. J. Pharm. Soc. Jpn., 1964, 84, 1186-1188.
115. Lizárraga-Guerra, R.; López, M.G. Content of free amino acids in Huitlacoche (Ustilago maydis) J. Agric. Food Chem., 1996, 44, 2556-2559. (Pubitemid 126453539)
116. Conti, P.; De Amici, M.; Roda, G.; Pinto, A.; Tamborini, L.; Madsen, U.; Nielsen, B.; Bräuner-Osborne, H.; De Micheli, C. Synthesis and pharmacological characterization at glutamate receptors of erythro-and threo-tricholomic acid and homologs thereof. Tetrahedron, 2007, 63, 2249-2256. (Pubitemid 46201690)
117. Pinto, A.; Conti, P.; De Amici, M.; Tamborini, L.; Madsen, U.; Nielsen, B.; Christesen, T.; Bräuner-Osborne, H.; De Micheli, C. Synthesis and pharmacological characterization at glutamate receptors of the four enantiopure isomers of tricholomic acid. J. Med. Chem., 2008, 51, 2311-2315. (Pubitemid 351506433)
118. Conti, P.; De Amici, M.; Grazioso, G.; Roda, G.; Barberis Negra, F.F.; Nielsen, B.; Stensboøl, T.B.; Madsen, U.; Bräuner-Osborne, H.; Frydenvang, K.; De Sarro, G.; Toma, L.; De Micheli, C. Design, synthesis, and pharmacological characterization of novel, potent NMDA receptor antagonists. J. Med. Chem., 2004, 47, 6740-6748. (Pubitemid 40063594)
119. De Carvalho, L.P.; Bochet, P.; Rossier, J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem. Int., 1996, 28, 445-452. (Pubitemid 26120215)
120. Erreger, K.; Geballe, M.T.; Dravid, S.M.; Snyder, J.P.; Wyllie, D.J.A.; Traynelis, S.F. Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J. Neurosci., 2005, 25, 7858-7866. (Pubitemid 41208658)
121. Zhenochin, S.P.; Piotrovsky, L.B.; Dumpis, M.A.; Maximyuk, P.; Lishko, P.V.; Tsyndrenko, AYa.; Krishtal, O.A. Analogs of a superacidic NMDA receptor agonist, N-phthalamoyl-L-glutamic acid (PhGA): activity and mode of interaction with the receptor recognition site Neurophysiology, 1999, 31, 359-369.
122. Kiskin A.Y.; Tsyndrenko, N.I.; Dumpis, M.A.; Piotrovsky, L.B.; Krishtal, O.A. A novel selective NMDA agonist, N-phthalamoyl-L-glutamic acid (PHGA). Neuroreport, 1991, 2, 29-32.
123. Koreshonkov, O.N.; Perestenko, P.V.; Dumpis, M.A.; Piotrovskii, L.B. Effect of N-phthalamoyl-L-glutamic acid, a selective NMDA receptor agonist, on binding of 3H-L-glutamate with hippocampal synaptic membranes. Bull. Exp. Biol. Med., 1992, 113, 749-751.
124. Sakai, R.; Kamiya, H.; Murata, M.; Shimamoto, K. Dysiherbaine: a new neurotoxic amino acid from the micronesian marine sponge Dysidea herbacea. J. Am. Chem. Soc., 1997, 119, 4112-4116. (Pubitemid 27239959)
125. Swanson, G.T.; Green, T.; Sakai, R.; Contractor, A.; Che, W.; Kamiya, H.; Heinemann, S.F. Differential activation of individual subunits in heteromeric kainate receptors. Neuron, 2002, 34, 589-598. (Pubitemid 34628755)
126. Cohen, J.L.; Limon, A.; Miledi, R.; Chamberlin, A.R. Design, synthesis, and biological evaluation of a scaffold for iGluR ligands based on the structure of (-)-dysiherbaine. Bioorg. Med. Chem. Lett., 2006, 16, 2189-2194. (Pubitemid 43351076)
127. Muir, K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol., 2007, 6, 53-60.
128. Whitten, J.P.; Harrison, B.L.; Weintraub, H.J.R.; McDonald, I.A. Modeling of competitive phosphono amino acid NMDA receptor antagonists. J. Med. Chem., 1992, 35, 1509-1514.
129. Low, S.J.; Roland, C.L. Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int. J. Clin. Pharmacol. Ther., 2004, 42, 1-14 (Pubitemid 38100854)
130. Chizh, B.A.; Headley, P.M.; Tzschentke, T.M. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol. Sci., 2001, 22, 636-641.
131. Chen, M.; Lu, T.J.; Chen, X.J.; Zhou, Y.; Chen, Q.; Feng, X.Y.; Xu, L.; Duan, W.H.; Xiong, Z.Q. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke, 2008, 39, 3042-3048.
132. Hallett, P.J.; Standaert, D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther., 2004, 102, 155-174. (Pubitemid 38681014)
133. Tang, Y.P.; Wang, H.; Feng, R.; Kyin, M.; Tsien, J.Z. Differential effects of enrichment on learning and memory function in NR2B transgenic mice. Neuropharmacol., 2001, 41, 779-790. (Pubitemid 32972196)
134. Zhuo, M. Plasticity of NMDA receptor NR2B subunit in memory and chronic pain. Mol. Brain, 2009, 2: 4.
135. Evans, R.H.; Francis, A.A.; Hunt, K.; Oakes, D.J.; Watkins, J.C. Antagonism of excitatory amino acid-induced responses and of synaptic excitation in the isolated spinal cord of the frog. Br. J. Pharmacol., 1979, 67, 591-603. (Pubitemid 10129086)
136. Fagg, G.E.; Olpe, H.R.; Pozza, M.F.; Baud, J.; Steinmann, M.; Schmutz, M.; Portet, C.; Baumann, P.; Thedinga, K.; Bittiger, H.; Allgeier, H.; Heckendorn, R.; Angst, C.; Brundish, D.; Dingwall, J.G. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br. J. Pharmacol., 1990, 99,791-797.
137. Hutchison, A.J.; Williams, M.; Angst, C.; De Jesus, R.; Blanchard, L.; Jackson, R.H.; Wilusz, E.J.; Murphy, D.E.; Bernard, P.S. 4-(Phosphonoalkyl)-and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors and anticonvulsant activity J. Med. Chem., 1989, 32, 2171-2178. (Pubitemid 19224183)
138. Johnson, G.; Ornstein, P.L. Competitive NMDA antagonists -A comprehensive analysis of molecular biological, structure activity and molecular modeling relationships. Curr. Pharm. Des., 1996, 2, 331-356. (Pubitemid 126475038)
139. Ornstein, P.L.; Klimkowski, V.J. Competitive NMDA receptor antagonists. In Excitatory amino acid receptors: design of agonists and antagonists Krogsgaard-Larsen, P., and Hansen, J.J., Eds.; Ellis Horwood: Chichester, 1992; pp 183-200.
140. Hays, S.J.; Bigge, C.F.; Novak, P.M.; Drummond, J.T.; Bobovski, T.P.; Rice, M.J.; Johnson, G.; Brahce, L.J.; Coughenour, L.L. New and versatile approaches to the synthesis of CPP-related competitive NMDA antagonists. Preliminary structure activity relationships and pharmacological evaluation J. Med. Chem., 1990, 33, 2916-2924. (Pubitemid 20312164)
141. Lehmann, J.; Schneider, J.; McPherson, S.; Murphy, D.E.; Bernard, P.; Tsai, C.; Bennett, D.A.; Pastor, G.; Steel, D.J.; Boehm, C. CPP, a selective Nmethyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo. J. Pharmacol. Exp. Ther., 1987, 240, 737-746. (Pubitemid 17043569)
142. Aebischer, B.; Frey, P.; Haerter H.P.; Herrling, P.L.; Mueller, W.; Olverman, H.J.; Watkins, J.C. Synthesis and NMDA antagonist properties of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CPP-ene). Helv. Chim. Acta, 1989, 72, 1043-1051. (Pubitemid 19203027)
143. Sills, M.A.; Fagg, G.; Pozza, M.; Angst, C.; Brundish, D.E.; Hurt, S.D.; Wilusz, E.J.; Williams, M. [3H]-CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur. J. Pharmacol., 1991, 192, 19-24.
144. Ornstein, P.L.; Schaus, J.M.; Chambers, J.W.; Huser, D.L.; Leander, J.D.; Wong, D.T.; Paschal, J.W.; Jones, N.D.; Deeter, J.B. Potent N-methyl-Daspartate receptor antagonists. J. Med. Chem., 1989, 32, 827-833.
145. Bennett, D.A.; Bernard, P.S.; Amrick, C.L.; Wilson, D.E.; Liebman, J.M.; Hutchison, A.J. Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther., 1989, 250, 454-460. (Pubitemid 19216126)
146. Ferkany, J.W.; Hamilton, G.S.; Patch, R.J.; Huang, Z.; Borosky, S.A.; Bednar, D.L.; Jones, B.E.; Zubrowski, R.; Willetts, J.; Karbon, E.W. Pharmacological profile of NPC 17742 [2R,4R,5S-(2-amino-4,5-(1,2-cyclohexyl)-7- phosphonoheptanoic acid)], a potent, selective and competitive N-methyl-D-aspartate receptor antagonist. J. Pharmacol. Exp. Ther.,1993, 264, 256-264. (Pubitemid 23309210)
147. Willetts, J.; Clissold, D.B.; Hartman, T.L.; Brandsgaard, R.R.; Hamilton, G.S.; Ferkany, J.W. Behavioral pharmacology of NPC 17742, a competitive N-methyl-D-aspartate (NMDA) antagonist. J. Pharmacol. Exp. Ther., 1993, 265, 1055-1062. (Pubitemid 23321001)
148. Mueller, W.; Lowe, D.A.; Neijt, H.; Urwyler, S.; Herrling, P.L.; Blaser, D.; Seebach D. Synthesis and N-methyl-D-aspartate (NMDA) antagonist properties of the enantiomers of amino-5-(phosphonomethyl)[1,1-biphenyl]-3-propanoic acid. Use of a new chiral glycine derivative. Helv. Chim. Acta, 1992, 75, 855-864.
149. Cheung, N.S.; O'Callaghan, D.; Ryan, M.C.; Dutton, R.; Wong, M.G.; Beart, P.M. Structure-activity relationships of competitive NMDA receptor antagonists. Eur. J. Pharmacol., 1996, 313, 159-162. (Pubitemid 26342220)
150. Elzey, T. 4-(Tetrazoleylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action. J. Med. Chem., 1991, 34, 90-97.
151. Schoepp, D.D.; Ornstein, P.L.; Leander, J.D.; Lodge, D.; Salhoff, C.R.; Zeman, S.; Zimmerman, D.M. Pharmacological characterization of LY233053: a structurally novel tetrazolee-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action. J. Pharmacol. Exp. Ther., 1990, 255, 1301-1308.
152. Ornstein, P.L.; Schoepp, D.D.; Arnold, M.B.; Jones, N.D.; Deeter, J.B.; Lodge, D.; Leander, J.D. NMDA antagonist activity of (+)-(2SR,4RS)-4-(1H- tetrazole-5-ylmethyl)piperidine-2-carboxylic acid resides with the (-)-2R,4S-isomer J. Med. Chem., 1992, 35, 3111-3115.
153. Feng, B.; Morley, R.M.; Jane, D. E.; Monaghan, D.T. The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacol., 2005, 48, 354-359. (Pubitemid 40249998)
154. Kinarsky, L.; Feng, B.; Skifter, D.; Morley, R.M.; Sherman, S.; Jane, D.E.; Monaghan, D.T. Identification of subunit-specific and antagonist specific amino acids in the NMDA receptor glutamate binding pocket. J. Pharmacol. Exp. Ther., 2005, 313, 1066-1074.
155. Blaise, M.C.; Sowdhamini, R.; Pradhan, N. Comparative analysis of different competitive antagonists interaction with NR2A and NR2B subunits of Nmethyl-D-aspartate (NMDA) ionotropic glutamate receptor. J. Mol. Model., 2005, 11, 489-502. (Pubitemid 41829671)
156. Grazioso, G.; Moretti, L.; Scapozza, L.; De Amici, M.; De Micheli, C. Development of a three-dimensional model for the N-methyl-D-aspartate NR2A subunit. J. Med. Chem., 2005, 48, 5489-5494. (Pubitemid 41213350)
157. Christie, J.M.; Jane, D.E; Monaghan, D.T. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J. Pharmacol. Exp. Ther., 2000, 292, 1169-1174. (Pubitemid 30136615)
158. Swanson, G.T.; Sakai, R. Ligands for ionotropic glutamate receptors. Prog. Mol. Subcell. Biol., 2009, 46, 123-157.
159. Prorok, M.; Castellino, F.J. The molecular basis of conantokin antagonism of NMDA receptor function. Curr. Drug Targets, 2007, 8, 633-642. (Pubitemid 46785061)
160. White, H.S.; McCabe, R.T.; Armstrong, H.; Donevan, S.D.; Cruz, L.J.; Abogadie, F.C.; Torres. J.; Rivier, J.E.; Paarmann, I.; Hollmann, M.; Olivera, B.M. In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus. J. Pharmacol. Exp. Ther., 2000, 292, 425-432. (Pubitemid 30026402)
161. Layer, R.T.; Wagstaff, J.D.; White, H.S. Conantokins: peptide antagonists of NMDA receptors. Curr. Med. Chem., 2004, 11, 3073-3084. (Pubitemid 39545576)
162. Hama, A.; Sagen, J. Antinociceptive effects of the marine snail peptides conantokin-G and conotoxin MVIIA alone and in combination in rat models of pain. Neuropharmacol., 2009, 56, 556-563.
163. Teichert, R.W.; Jimenez, E.C.; Twede, V.; Watkins, M.; Hollmann, M.; Bulaj, G.; Olivera, B.M. Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J. Biol. Chem., 2007, 282, 36905-36913.
164. Twede, V.D.; Teichert, R.W.; Walker, C.S.; Gruszczyski, P.; Kamierkiewicz, R.; Bulaj, G.; Olivera, B.M. Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor. Biochemistry, 2009 48, 4063-4073.
165. Klein, R.C.; Prorok, M.; Galdzicki, Z.; Castellino, F.J. The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-methyl-D-aspartate receptors. J. Biol. Chem., 2001, 276, 26860-26867.
166. Sheng, Z.; Dai, Q.; Prorok, M.; Castellino, F.J. Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides. Neuropharmacol., 2007, 53, 145-156. (Pubitemid 47125955)
167. Buller, A.L.; Monaghan, D.T. Pharmacological heterogeneity of NMDA receptors: characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes. Eur. J. Pharmacol., 1997, 320, 87-94. (Pubitemid 27076261)
168. Feng, B.; Tse, H.W.; Skifter, D.A.; Morley, R.; Jane, D.E.; Monaghan, D.T. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid. Br. J. Pharmacol., 2004, 141, 508-516. (Pubitemid 38297013)
169. Morley, R.M.; Tse, H.W.; Feng, B.; Miller, J.C.; Monaghan, D.T.; Jane, D.E. Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J. Med. Chem., 2005, 48, 2627-2637. (Pubitemid 40516452)
170. Ortwine, D.F.; Malone, T.C.; Bigge, C.F.; Drummond , J.T.; Humblet, C.; Johnson, G.; Pinter, G.W. Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists. J. Med. Chem., 1992, 35, 1345-1370.
171. Cordi, A.A.; Vazquez, M.L. Phosphono-isoquinoline compounds useful in reducing neurotoxic injury. Eur. Patent 4997821 March 5, 1991.
172. Ornstein, P.L. In: Drug Design for Neuroscience; Kozikowski, A.P. Ed.; Raven Press, Ltd.: N.Y., 1993; pp 285-309.
173. Bigge, C.F.; Drummond, J.T.; Johnson, G.; Malone, T.; Probert, A.W.Jr.; Marcoux, F.W.; Coughenour L.L.; Brahce, L.J. Exploration of phenyl-spaced 2-amino-(5-9)-phosphonoalkanoic acids as competitive N-methyl-D-aspartic acid antagonists. J. Med. Chem., 1989, 32, 1580-1590. (Pubitemid 19205369)
174. Li, J.H.; Bigge, C.F.; Williamson, R.M.; Borosky, S.A.; Vartanian, M.G.; Ortwine, D.F. Potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonists are substrates for a neutral amino acid uptake system in chinese hamster ovary cells. J. Med. Chem., 1995, 38,1955-1965.
175. Vazquez, M.L.; Garland, D.J.; Sun, E.T.; Cler, J.A.; Mick, S.J.; Hood, W.F.; Monahan, J.B.; Iyengar, S.; Rao, T.S. Characterization of 3-carboxy-5-phosphono-1,2,3,4-tetrahydroisoquinoline (SC-48981), a potent competitive N-methy-D-aspartate (NMDA) receptor antagonist, in vitro and in vivo. Neurosci. Lett., 1992, 135, 149-152.
176. Ornstein, P.L.; Schoepp, D.D.; Arnold, M.B.; Augenstein, N.K.; Lodge, D.; Millar, J.D.; Chambers, J.; Campbell, J.; Paschal, J.W. 6-Substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists. J. Med. Chem., 1992, 35, 3547-3560.
177. Ornstein, P.L.; Arnold, M.B.; Augenstein, N.K.; Deeter, J.B.; Leander, J.D.; Lodge, D.; Calligaro, D.O.; Schoepp, D.D. Unusual stereochemical preferences of decahydroiosquinoline-3-caboxylic acid competitive NMDA antagonists. Bioorg. Med. Chem. Lett., 1993, 3, 2067-2072. (Pubitemid 23349755)
178. Schoepp, D.D.; Ornstein, P.L.; Salhoff, C.R.; Leander, J.D. Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA antagonist. J. Neural. Trasm., 1991, 85, 131-143.
179. Auberson, Y.P.; Allgeier, H.; Bischoff, S.; Lingenhoehl, K.; Moretti, R.; Schmutz, M. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg. Med. Chem. Lett., 2002, 12, 1099-1102. (Pubitemid 34242811)
180. Honoré, T.; Lauridsen, J.; Krogsgaard-Larsen, P. The binding of [3H]AMPA, a structural analogue of glutamic acid, to rat brain membranes. Neurochem., 1982, 38, 173-178. (Pubitemid 12189209)
181. Baron, B.M.; Siegel, B.W.; Harrison, B.L.; Gross, R.S.; Hawes, C.; Towers, P. [3H]MDL 105,519, a high-affinity radioligand for the N-methyl-Daspartate receptor-associated glycine recognition site. J. Pharmacol. Exp. Ther., 1996, 279, 62-68.
182. Liu, L.; Wong, T.P.; Pozza, M.F.; Lingenhoehl, K.; Wang, Y.; Sheng, M.; Auberson, Y.P.; Wang, Y.T. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science, 2004, 304, 1021-1024. (Pubitemid 38638102)
183. Massey, P.V.; Johnson, B.E.; Moult, P.R.; Auberson Y.P.; Brown, M.W.; Molnar, E.; Collingridge, G.L.; Bashir, Z.I. Differential roles of NR2A and NR2B-containing NMDA receptors in. cortical long-term potentiation and long-term depression. J. Neurosci., 2004, 24, 7821-7828. (Pubitemid 39215685)
184. Zhou, M.; Baudry, M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J. Neurosci., 2006, 26, 2956-2963.
185. Frizelle, P.A.; Chen, P.E.; Wyllie, D.J.A Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin- 5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B NMDA receptors: implications for studies of synaptic transmission. Mol. Pharmacol., 2006, 70, 1022-1032. (Pubitemid 44268459)
186. Neyton, J.; Paoletti, P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J. Neurosci., 2006, 26, 1331-1333. (Pubitemid 43237003)
187. Baudy, R.B.; Greenblatt, L.P.; Jirkovsky, I.L.; Conklin, M.; Russo, R.J.; Bramlett, D.R.; Emrey, T.A.; Simmonds, J.T.; Kowal, D.M.; Stein, R.P.; Tasse, R.P. Potent quinoxaline-spaced phosphono -amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation. J. Med. Chem., 1993, 36, 331-342. (Pubitemid 23067542)
188. Baudy, R.B.; Fletcher, H.3rd; Yardley, J.P.; Zaleska, M.M.; Bramlett, D.R.; Tasse, R.T.; Kowal, D.M.; Katz, A.H.; Moyer, J.A.; Abou-Gharbia, M. Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-amino acid competitive NMDA antagonists of the AP-6 type. J. Med. Chem., 2001, 44, 1516-1529. (Pubitemid 32852195)
189. Levin, M.D.; Kaszynsky, P.; Michl, J. Bicyclo[1.1.1]pentanes, [n]staffanes, [1.1.1]propellanes, and tricyclo[2.1.0.02,5]pentanes. Chem. Rev., 2000, 100, 169-234.
190. Pritz, S.; Pätzel, M.; Szeimies, G.; Dathe, M.; Bienert, M. Synthesis of a chiral amino acid with bicyclo[1.1.1]pentane moiety and its incorporation into linear and cyclic antimicrobial peptides. Org. Biomol. Chem., 2007, 5, 1789-1794. (Pubitemid 46794170)
191. Pellicciari, R.; Raimondo, M.; Marinozzi, M.; Natalini, B.; Costantino, G.; Thomsen C. (S)-(+)-2-(3′-Carboxybicyclo[1.1.1]pentyl)-glycine, a structurally new group I metabotropic glutamate receptor antagonist. J. Med. Chem., 1996, 39, 2874-2876. (Pubitemid 26251024)
192. Mannaioni, G.; Attucci, S.; Missanelli, A.; Pellicciari, R.; Corradetti R.; Moroni, F. Biochemical and electrophysiological studies on (S)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine (CBPG), a novel mGlu5 receptor agonist endowed with mGlu1 receptor antagonist activity. Neuropharmacol., 1999, 38, 917-926. (Pubitemid 29240608)
193. Filosa, R.; Fulco, M.C.; Marinozzi, M.; Giacchè, N.; Macchiarulo, A.; Peduto, A.; Massa, A.; De Caprariis, P.; Thomsen, C.; Christoffersen, C.T.; Pellicciari, R. Design, synthesis and biological evaluation of novel bicyclo[1.1.1.]pentane-based -acidic amino acids as glutamate receptors ligands. Bioorg. Med. Chem., 2009, 17, 242-250.
194. Conti, P.; De Amici, M.; Joppolo di Ventimiglia, S.; Stensboøl, T.B.; Madsen, U.; Bräuner-Osborne, H.; Russo, E.; De Sarro, G.; Bruno, G.; De Micheli C. Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids. J. Med. Chem., 2003, 46, 3102-3108. (Pubitemid 36780940)
195. Conti, P.; De Amici, M.; Grazioso, G.; Roda, G.; Pinto, A.; Hansen K.B.; Nielsen B.; Madsen U.; Brauner-Osborne H.; Egebjerg J.; Vestri V.; Pellegrini-Giampietro D.E.; Sibille P.; Acher F.C.; De Micheli C. Synthesis, binding affinity at glutamic acid receptors, neuroprotective effects, and molecular modeling investigation of novel dihydroisoxazole amino acids. J. Med. Chem., 2005, 48, 6315-6325. (Pubitemid 41430482)
196. Conti, P.; Pinto, A.; Tamborini, L.; Grazioso, G.; De Sarro, G.; Brauner-Osborne, H.; Szabo, G.; Harsing, L.G.; De Micheli C. Synthesis of conformationally constrained glutamic acid homolgues and investigation of their pharmacological profile. ChemMedChem, 2007, 2, 1639-1647.
197. Conti, P.; Pinto, A.; Tamborini, L.; Madsen, U.; Nielsen, B.; Brauner-Osborne, H.; Hansen, K.B.; Landucci, E.; Pellegrini-Giampietro, D.E.; De Sarro, G.; Donato Di Paola, E.; De Micheli, C. Novel 3-carboxy-and 3-phosphonopyrazoline amino acids as potent and selective NMDA receptor antagonists: design, synthesis, and pharmacological characterization. ChemMedChem, 2010, 5, 1465-1475.